MOTS-c
$64.99
10 MG

In stock
Buy Semax peptide at Velora Research. This synthetic heptapeptide is derived from a modified ACTH (4-7) fragment and is supplied as a 10mg lyophilized research compound for in vitro and preclinical investigation by qualified laboratories. Each batch is independently HPLC and mass-spec verified at 99% or higher purity, with a downloadable Certificate of Analysis tied to the lot number. Strictly for laboratory research use, not for human or veterinary use.
Specifications
Semax is a synthetic seven-amino-acid peptide derived from a fragment of adrenocorticotropic hormone (ACTH). Velora Research supplies Semax peptide as a 10mg lyophilized vial for in vitro and preclinical investigation by qualified laboratories and research professionals.
Every batch of Velora’s Semax peptide is independently verified by a third-party analytical laboratory using high-performance liquid chromatography (HPLC) for purity and mass spectrometry for identity. The batch-specific Certificate of Analysis is published on our COAs page and linked from this product page so researchers can confirm identity, purity, and molecular integrity before placing the compound into a study.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH (4-7) fragment, while the C-terminal Pro-Gly-Pro extension stabilizes the peptide against rapid enzymatic degradation. The molecular weight is approximately 813 g/mol. Semax was originally developed in the 1980s by the Institute of Molecular Genetics of the Russian Academy of Sciences and is sometimes referred to in literature simply as MEHFPGP.
In published preclinical and clinical research, Semax peptide has been characterized as a regulatory peptide acting through multiple signaling systems, with documented effects in cell-culture and animal models that include the BDNF (brain-derived neurotrophic factor) pathway, the dopaminergic system, and the melanocortin receptor family.
Researchers searching for what Semax peptide is used for are generally asking about the published research areas in which it has been characterized. Across peer-reviewed preclinical and clinical literature (primarily Russian and Eastern European groups), the principal research areas include:
Velora Research supplies the Semax peptide solely as a research compound for further investigation of these and related research questions. All language above is research-frame and describes published preclinical literature. Nothing in this section constitutes a claim that Semax produces any specific outcome in humans, animals, or therapeutic applications.
Semax has a regulatory profile that is worth understanding before purchase. In Russia, Semax is approved as a clinical pharmaceutical under regional regulators for specific medical indications and is marketed under the Semax brand in a 0.1% intranasal formulation. In the United States, the European Union, and most other Western jurisdictions, Semax is not approved for any therapeutic use and is supplied solely as a research compound.
Velora Research’s Semax peptide product is a research-grade compound for in vitro and preclinical laboratory investigation. It is not the same product as the Russian Semax pharmaceutical, is not packaged or quality-controlled for human use, and is not for any therapeutic, nutritional, or cosmetic application.
| Attribute | Specification |
| Research name | Semax peptide |
| Alternate names | MEHFPGP, Semax-ACTH (4-7) Pro-Gly-Pro |
| Class | Synthetic heptapeptide, ACTH fragment analog |
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro |
| Available size | 10mg |
| Form | Lyophilized white powder |
| Purity | 99% or higher (HPLC verified) |
| Molecular formula | C37H51N9O10S |
| Molecular weight | ~813.93 g/mol |
| CAS number | 80714-61-0 |
| Storage (lyophilized) | -20°C, sealed, dry, dark |
| Storage (reconstituted) | 2 to 8°C, single-use aliquots recommended |
| Verification | Independent third-party HPLC and mass spectrometry per batch |
| COA access | Batch-specific COA at verify.janoshik.com (linked from this page) |
Velora Research lists Semax peptide 10mg at a single transparent tier. The 10mg vial is sized to cover most pilot studies and multi-arm cell-culture experiments without re-ordering:
| Vial size | Price (USD) | Best for |
| 10mg | $55.00 | Pilot studies, BDNF and neurotrophic-factor research models, dopaminergic-signaling assays, receptor-binding research |
Free US shipping applies on orders over $200. Most orders process within 1 to 2 business days. International orders are accepted in accordance with applicable research regulations.
Researchers screening Semax peptide suppliers typically evaluate vendors on five criteria. Velora was built around all five:
Velora’s Semax peptide ships as a lyophilized powder. For in vitro studies, researchers typically reconstitute with bacteriostatic water (0.9% benzyl alcohol) or, for cell-culture protocols, with sterile water at a concentration matched to the assay. A common pilot ratio for the 10mg vial is 2 mL of bacteriostatic water, yielding a 5 mg/mL stock solution. Adjust per study design.
Published research protocols use two principal administration routes in animal-model studies: intranasal and subcutaneous. The intranasal route is used in much of the Russian Semax research literature, which also drives the high search interest in ‘semax nasal spray’ formulations. For Velora’s research-grade Semax peptide, any administration route in a research protocol should be selected and validated per the peer-reviewed literature and institutional approvals.
Velora Research supplies bacteriostatic water as a separate product. Please refer to the peer-reviewed literature for protocol-specific reconstitution and handling parameters.
Researchers evaluating Semax peptide for purchase often compare it to Selank, the other widely studied Russian-developed regulatory peptide. Summary of how the two differ at the mechanism level, drawn from published research:
| Attribute | Semax peptide | Selank peptide |
| Origin | Synthetic ACTH (4-7) analog | Synthetic tuftsin analog |
| Sequence length | 7 amino acids | 7 amino acids |
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Thr-Lys-Pro-Arg-Pro-Gly-Pro |
| Primary research focus | BDNF and neurotrophic-factor research, cerebrovascular research models, dopaminergic-system research | Anxiolytic-research models, GABA-system research, immune-modulation research |
| Regulatory status (Russia) | Approved clinical pharmaceutical (Semax brand) | Approved clinical pharmaceutical (Selank brand) |
| Regulatory status (US) | Research use only | Research use only |
Both peptides are supplied by Velora Research as research compounds for in vitro and preclinical investigation only. Researchers running comparative studies of the two compounds may consider purchasing both for direct head-to-head assay designs.
Semax peptide is a synthetic seven-amino-acid heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, derived from a modified fragment of adrenocorticotropic hormone (ACTH). It was originally developed in the 1980s by the Institute of Molecular Genetics in Russia. Velora supplies it as a 10mg lyophilized research compound for in vitro and preclinical investigation only.
In published preclinical and clinical literature, Semax peptide has been characterized in research areas including BDNF and neurotrophic-factor expression, cerebrovascular research models, cognitive-research animal assays, dopaminergic-system signaling, and melanocortin-receptor binding studies. These are areas of published research interest only. Velora Research makes no claim that Semax peptide produces any specific outcome in humans, animals, or therapeutic applications. The compound is supplied for further in vitro and preclinical investigation only.
No. Semax peptide is not approved by the FDA, the European Medicines Agency, or other major Western regulators for any therapeutic indication. It is approved as a clinical pharmaceutical in Russia under regional regulators for specific medical indications, but the Russian clinical product is distinct from Velora’s research-grade Semax peptide. Velora’s product is supplied strictly for laboratory research use.
Velora Research supplies Semax peptide 10mg with batch-level third-party HPLC and mass-spec verification. Each Certificate of Analysis is tied to the specific lot number printed on the vial and is downloadable from the product page. Pricing reflects research-grade verification rather than bulk commodity supply.
Every batch is independently tested by a third-party analytical laboratory using high-performance liquid chromatography (HPLC) for purity and mass spectrometry for identity confirmation. The Certificate of Analysis is published on our /coas/ page and linked from this product page by batch number.
Store the lyophilized vial sealed at -20°C in a dry, dark environment. Once reconstituted with bacteriostatic water, refrigerate at 2 to 8°C and use within the stability window established by the research protocol. Avoid repeat freeze-thaw cycles.
Both are seven-amino-acid synthetic regulatory peptides developed in Russia, and both are approved as clinical pharmaceuticals in that jurisdiction while remaining research-use only elsewhere. Semax is derived from an ACTH fragment and is most studied in the BDNF, neurotrophic-factor, and cerebrovascular literature. Selank is derived from the tuftsin sequence and is most studied in the anxiolytic and GABA-system literature. Velora supplies both as research compounds and many researchers purchase both for comparative protocols.
No. Velora Research supplies Semax peptide strictly for laboratory research conducted by qualified institutions and research professionals. The product is not packaged or quality-controlled for personal, nutritional, cosmetic, or therapeutic use. Purchasers confirm research-use-only intent at checkout.
Velora Research accepts international orders for laboratory research use only. Buyers are responsible for ensuring compliance with all applicable local, state, and national regulations in their jurisdiction prior to purchasing.